摘要
目的 比较单独应用替莫唑胺（tmozolomide,TMZ）与联合运用替尼泊甙（teniposide,VM-26）、洛莫司汀（lomustine,CCNU）对颅内恶性胶质瘤治疗的有效性。方法 颅内恶性胶质瘤患者52例,随机分成两组,给予TMZ（200mg·m^2·d^-1）口服,5天为1疗程;VM-26（60 mg·m^2·d^-1）,第1-2天静脉给药,CCNU（60 mg·m^2·d^-1）,第3-4天口服给药,4天为1疗程。两组均进行不少于3个疗程的化疗;观察患者生存期、有效率及不良反应。结果 两组的生存时间及有效率差异无统计学意义,TMZ组平均无进展生存期为（37.1±2.4）周,联合用药组为（33.1±2.7）周,TMZ组平均总生存时间为（73.3±4.2）周,联合用药组为（66.7±3.2）周,经对数秩检验P〉0.05;TMZ组有效率为42.3%,联合用药组为34.6%（χ2=0.33,P〉0.5）。但TMZ对骨髓的抑制明显轻于联合用药组,其中TMZ组：Ⅰ度24.6%、Ⅱ度2.3%;联合用药组：Ⅰ度39.3%、Ⅱ度45.7%,两组比较差异有统计学意义（uc=2.47,P〈0.05）。结论 TMZ较VM-26、CCNU联合药物化疗具有更好的耐受性,但两者在改善患者生存状况方面无明显不同;由于本研究样本较少,需要进一步积累、验证。
Objective To determine the efficacy of tmozolomlde（TMZ） vs teniposide（VM-26） and lomustine （CCNU） in the patients with malignant gliomas. Methods Fifty-two in-patients with pathological identified malignant glioma were enrolled. All the patients were randomized into two groups. TMZ（200 mg·m^2·d^-1 ） was given orally in lst-Sth day;VM-26（60 mg·m^2·d^-1） was given intravenously in 1-2 d and CCNU（60 mg·m^2·d^-1） was given orally in 3-4 d. The treatment study was completed in three consecutive therapeutic courses at least. The survival time, efficacy and side effect were observed. Results There were no significant differences in the survival time and efficacy between two groups（ P 〉0.05） ;there was significant difference in the side effect, however（ P 〈0.05）. Conclusion Although the tolerance of the patients in the TMZ group was better than that of the other group, the survival of the patients with malignant glioma was not improved at all in both groups. A longer time and more comprehensive study are necessary in consideration of less samples.
出处
《临床荟萃》
CAS
北大核心
2007年第16期1154-1156,共3页
Clinical Focus
